A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults
Latest Information Update: 21 Nov 2024
Price :
$35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Pruritus
- Focus Registrational; Therapeutic Use
- Acronyms STYLE2
- Sponsors Sanofi
- 21 Nov 2024 New trial record